AI Health Co.
The Story
faces allegations from patients claiming illegal sharing of their genetic data. A lawsuit has been filed, asserting unauthorized disclosure of highly sensitive personal information.
Why It Matters
This story is a stark reminder about data governance in pharma. For CROs and biotech, patient genetic data is highly sensitive and its mishandling invites catastrophe. The EU AI Act, with its August 2026 enforcement, will not tolerate such missteps. Your AI strategy must prioritize data sovereignty and internal controls, especially with third-party tools.
What To Do About It
What I'd check first is your data processing agreements for all AI tools. Ensure they explicitly address EU data sovereignty and GDPR compliance. For sensitive patient data, investigate local-first AI deployment options or private cloud solutions to maintain control.
